Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Recent & Breaking News (OTCQB:CYTOF)

Biotech Stocks on Investors' Radar -- Portola Pharma, bluebird bio, Auris Medical, and Cerulean Pharma

PR Newswire September 22, 2016

Auris Medical Announces AAO-HNSF Annual Meeting Activities

GlobeNewswire September 13, 2016

Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness

GlobeNewswire September 9, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  September 2, 2016

Mid-Afternoon Market Update: Crude Oil Up 2.7%; Canadian Solar Shares Rise Following Q2 Results

Benzinga.com  August 18, 2016

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  August 18, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  August 18, 2016

Auris Medical Provides Business Update and Reports Second Quarter 2016 Financial Results

GlobeNewswire August 18, 2016

Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus

GlobeNewswire August 18, 2016

18 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  August 17, 2016

Auris Medical to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on Thursday, August 18, 2016

GlobeNewswire August 16, 2016

Auris Medical Secures Loan Facility of Up To $20 Million

GlobeNewswire July 19, 2016

Auris Medical Gets FDA's Fast Track Designation For Keyzilen In Acute Peripheral Tinnitus

Benzinga.com  July 18, 2016

FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus

GlobeNewswire July 18, 2016

Auris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12

GlobeNewswire July 8, 2016

Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus

GlobeNewswire June 28, 2016

Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness

GlobeNewswire June 17, 2016

Auris Medical to Present at the JMP Securities Life Sciences Conference on Wednesday, June 22

GlobeNewswire June 16, 2016

Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus

GlobeNewswire June 14, 2016

Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program on June 14 in New York City

GlobeNewswire June 7, 2016